Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.

Bi Y, Zhang B, Xu W, Yang H, Feng W, Li C, Tong G, Li M, Wang X, Shen S, Zhu B, Weng J, Zhu D

Acta diabetologica14 Aug 2014Cited by 59 (Europe PMC)

PMID25118999DOI10.1007/s00592-014-0638-3PepBankPUB-25118999

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, body weight decreased with exenatide.
In plain wordsIn patients with diabetes, body weight decreased with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Body weight, waist, and serum triglycerides decreased with exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899902
02HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, waist circumference decreased with exenatide.
In plain wordsIn patients with diabetes, waist circumference decreased with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Body weight, waist, and serum triglycerides decreased with exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899903
03HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, serum triglycerides decreased with exenatide.
In plain wordsIn patients with diabetes, serum triglycerides decreased with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerum triglycerides
Study
n: not reported in source
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Body weight, waist, and serum triglycerides decreased with exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899904
04HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, intrahepatic fat decreased by 68 % with exenatide, and it also decreased with insulin (-58 %) and pioglitazone (-49 %).
In plain wordsIn patients with diabetes, liver fat fell 68 % from baseline with exenatide, and it also fell with insulin and pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIntrahepatic fat
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Intrahepatic fat change
−68%
exenatide
Source sentences
Summary
After interventions, IHF significantly reduced with three treatments (exenatide Δ = -68 %, insulin Δ = -58 %, pioglitazone Δ = -49 %).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899905
05HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, visceral fat decreased by 36 % with exenatide.
In plain wordsIn patients with diabetes, visceral fat decreased by 36 % with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVisceral fat
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Visceral fat change
−36%
exenatide
Source sentences
Summary
Exenatide reduced VF (Δ = -36 %) and SF (Δ = -13 %), and pioglitazone decreased VF (Δ = -30 %) with no impact on SF, whereas insulin had no impact on VF or SF.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899906
06HumanRandomized controlled trialEfficacy outcome
In drug-naive diabetes, subcutaneous fat decreased by 13 % with exenatide.
In plain wordsIn patients with diabetes, fat beneath the skin decreased by 13 % with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSubcutaneous fat
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Subcutaneous fat change
−13%
exenatide
Source sentences
Summary
Exenatide reduced VF (Δ = -36 %) and SF (Δ = -13 %), and pioglitazone decreased VF (Δ = -30 %) with no impact on SF, whereas insulin had no impact on VF or SF.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
Report a problemFND-2511899907

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In drug-naive diabetes, HbA1c declined in all groups, including exenatide, insulin and pioglitazone.
In plain wordsHbA1c fell in all three groups, including the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 33
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
HbA1c declined significantly in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899901
08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In drug-naive diabetes, TNFα decreased with exenatide, as it did with insulin and pioglitazone.
In plain wordsTNFα decreased with exenatide and both other treatments in patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTNFα
Study
n = 33
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Levels of TNFα (exenatide/insulin/pioglitazone) decreased, and levels of adiponectin (exenatide/pioglitazone) increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899908
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In drug-naive type 2 diabetes, adiponectin increased in both the exenatide and pioglitazone groups.
In plain wordsIn patients with diabetes, adiponectin increased in both the exenatide and pioglitazone groups.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Levels of TNFα (exenatide/insulin/pioglitazone) decreased, and levels of adiponectin (exenatide/pioglitazone) increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899909
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, liver fat change correlated with HbA1c change without an exenatide-specific estimate.
In plain wordsAcross the trial, liver fat change was linked to HbA1c change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableLiver fat change correlation with HbA1c
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Analysis showed that ΔIHF correlated with ΔHbA1c and Δweight.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899910
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, liver fat change correlated with weight change without an exenatide-specific estimate.
In plain wordsAcross the trial, liver fat change was linked to weight change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableLiver fat change correlation with weight
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Analysis showed that ΔIHF correlated with ΔHbA1c and Δweight.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899911
12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, liver fat change correlated with triglyceride change, but the association was not significant after BMI adjustment.
In plain wordsAcross the trial, liver fat and triglyceride changes were linked, but the link was not significant after body size adjustment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLiver fat change correlation with triglycerides
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Besides, ΔIHF correlated with Δtriglycerides and ΔTNFα, but the correlations fell short of significance after BMI adjustment.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899912
13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, liver fat change correlated with TNFα change, but the association was not significant after BMI adjustment.
In plain wordsAcross the trial, liver fat and TNFα changes were linked, but the link was not significant after body size adjustment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLiver fat change correlation with TNFα
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Besides, ΔIHF correlated with Δtriglycerides and ΔTNFα, but the correlations fell short of significance after BMI adjustment.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899913
14HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, HbA1c change explained 41.5 % of liver fat change variance.
In plain wordsAcross the trial, HbA1c change explained 41.5 % of variation in liver fat change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableLiver fat variance explained by HbA1c
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Measurements
Variance of ΔIHF explained by ΔHbA1c
41.5%
linear regression, ΔHbA1c alone
Source sentences
Summary
By linear regression analysis, ΔHbA1c alone explained 41.5 % of the variance of ΔIHF, and ΔHbA1c + Δweight explained 57.6 % of the variance.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899914
15HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
Across the diabetes trial, HbA1c and weight changes explained 57.6 % of liver fat change variance.
In plain wordsAcross the trial, HbA1c and weight changes explained 57.6 % of variation in liver fat change.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableLiver fat variance explained by HbA1c and weight
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Measurements
Variance of ΔIHF explained by ΔHbA1c + Δweight
57.6%
linear regression, ΔHbA1c + Δweight
Source sentences
Summary
By linear regression analysis, ΔHbA1c alone explained 41.5 % of the variance of ΔIHF, and ΔHbA1c + Δweight explained 57.6 % of the variance.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three drug-naive T2DM patients (age 52.7 ± 1.7 years, HbA1c 8.7 ± 0.2 %, body mass index 24.5 ± 0.5 kg/m(2)) were randomized into exenatide, insulin, or pioglitazone for 6 months.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2511899915

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.